Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Yahoo Finance • 8 hours ago

Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading

Asian equities traded in the US as American depositary receipts were tracking modestly higher Wednes PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • yesterday

Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

Ginkgo generates antibody data at scale and trains models for drug manufacturability and developability. Apheris' federated infrastructure enables participating pharmaceutical companies to use those models and further fine-tune them on the... Full story

Yahoo Finance • 9 days ago

Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development

Iambic Therapeutics, Inc., an AI drug discovery company backed by Nvidia Corp.(NASDAQ:NVDA) and the Qatar Investment Authority, filed for an initial public offering, according to an S-1 filing with the SEC on Monday. Plans to List on Nasd... Full story

Yahoo Finance • 12 days ago

Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?

Bristol Myers BMY recently announced positive two-year results from the late-stage POETYK PsA-2 study on Sotyktu (deucravacitinib), including its open-label extension (OLE). The two-year data provide additional support for Sotyktu's comme... Full story

Yahoo Finance • 13 days ago

Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe plaque psoriasis. The target action date fal... Full story

Yahoo Finance • 16 days ago

Hummingbird Bioscience Appoints Dr. James Garner as President

Hummingbird Bioscience Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscienc... Full story

Yahoo Finance • 16 days ago

Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Monday Trading

Asian equities traded in the US as American depositary receipts started the trading week heading sha PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 16 days ago

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer. Amge... Full story

Yahoo Finance • 17 days ago

Best Value Stocks to Buy for September 14th

Here are three stocks with buy rank and strong value characteristics for investors to consider today, September 14: Signet Jewelers Limited SIG: This global retail giant of diamond jewellery carries a Zacks Rank #1, and has witnessed the... Full story

Yahoo Finance • 17 days ago

Best Income Stocks to Buy for September 14th

Here are three stocks with buy rank and strong income characteristics for investors to consider today, September 14: Ternium S.A. TX: This steel products company has witnessed the Zacks Consensus Estimate for its current year earnings inc... Full story

Yahoo Finance • 22 days ago

Protagonist Therapeutics Announces $300 Million Share Repurchase Program

NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million... Full story

Yahoo Finance • 26 days ago

MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?

U.S. Food and Drug Administration approval of MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). The amount consists of an additio... Full story

Yahoo Finance • 28 days ago

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at val... Full story

Yahoo Finance • 30 days ago

Chris Benecchi Named Inventiva’s New Chief Operating Officer

By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company's ope... Full story

Yahoo Finance • 30 days ago

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.

You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Jo... Full story

Yahoo Finance • last month

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

MIMRYLO LogoMIMRYLO Packaging MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV) MIMRYLO Has Been Shown to Maintain Hematocrit Contro... Full story

Yahoo Finance • last month

Asian Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading

Asian equities traded in the US as American depositary receipts were tracking lower Tuesday morning, declining 1.03% to 2,988.00 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by pharmaceutical company Takeda Pharmaceut... Full story

Yahoo Finance • 2 months ago

Takeda Pharmaceutical (TSE:4502) Wins ORZEYFUL Approval, Where Does Fair Value Sit?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after U.S. regulators approved ORZEYFUL for adult narcoleps... Full story

Yahoo Finance • 2 months ago

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchi... Full story